The file g61029.mp4 relates to clinical trial results for Kintor Pharmaceuticals' GT20029, a topical androgen receptor degrader designed to treat androgenetic alopecia. Phase 2 trials showed statistically significant hair growth, with the treatment aiming to minimize systemic side effects through localized application. For more information, visit Kintor Pharmaceutical.